RxDoctor Payments Data

Anthony Gyang, MD

Gynecology · Saint Cloud, FLNPI 1982861340

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $750 of the $1,076 with a category attached, or 69.7%. Medical Device Business Services, Inc. accounts for 69.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $778 and has fallen 82.5% since, to $136 in 2024.

$1,076in general payments, 2019–2025

Across 13 payments — averaging $82.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$750
  • AbbVie$127
  • Astellas Pharma US Inc$122
  • Caldera Medical, Inc$57
  • Agile Therapeutics, Inc.$20
$128,383in research payments, 2019–2025

Across 41 payments — averaging $3131.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Exeltis, USA Inc.$125K
  • AbbVie$3K

What the payments were for

  • Consulting fees$75070%
  • Food & beverage$22621%
  • Education$1009%

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,076 in reported general payments places this provider in the 55th percentile of 290 gynecology providers in Florida.

See all gynecology providers in Florida

Medicare billing

Part B allowed, 2024
$38,507
Medicare patients
75
Services billed
230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron33$27,084
MyrbetriqMirabegron38$18,646
Estradiol99$5,721
Tolterodine Tartrate ErTolterodine Tartrate13$2,312
Solifenacin Succinate32$1,085
Tranexamic Acid14$785
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst28$702
Gabapentin34$546
Cephalexin36$480
Estradiol (Once Weekly)Estradiol12$464
ValacyclovirValacyclovir Hcl15$460
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip25$394
Clobetasol Propionate11$318
Nortriptyline Hcl14$301
Tamsulosin Hcl20$267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$122$18,64638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 290 gynecology providers in Florida.

Other gynecology in Saint Cloud

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →